According to its low brain penetrance and to its CB1R inverse agonist properties, we further believe that the chemical structure of JM-00266 may serve as a template to design derivatives that might become of great interest as new drugs for modulating peripheral ECS tone and improving metabolic disorders associated with obesity. Here, CNR1 is linked to metabolic disease.